首页|基于CCL2/CCR2信号轴的肿瘤免疫治疗药物的研究进展

基于CCL2/CCR2信号轴的肿瘤免疫治疗药物的研究进展

扫码查看
趋化因子配体2(C-C motif chemokine ligand 2,CCL2)及其受体CCR2与肿瘤的发生、发展密切相关.CCL2/CCR2信号轴通过多种机制促进肿瘤进展,一方面CCL2与肿瘤细胞表面的CCR2结合促进肿瘤的生长/存活和转移;更为重要的是CCL2可以招募多种免疫抑制细胞在肿瘤微环境中聚集,抑制免疫细胞的功能和活性,促进肿瘤进展.本文综述了CCL2/CCR2信号轴以及其在肿瘤及肿瘤微环境中的作用,并重点介绍了靶向CCL2/CCR2信号轴药物的临床研究进展,以期深入并全面了解CCL2/CCR2信号轴在肿瘤进展中的作用机制,开发更有效的肿瘤免疫治疗药物.
Research progress of drugs for cancer immunotherapy based on CCL2/CCR2 signaling axis
C-C motif chemokine ligand 2(CCL2)and its receptor CCR2 are closely related to tumorigenesis and tumor progression.The CCL2/CCR2 signaling axis promotes tumor progression through multiple mechanisms:CCL2 binds to CCR2 on the surface of tumor cells,and thus promotes tumor growth/survival and metastasis;more importantly,CCL2 recruits a variety of immunosuppressive cells to aggregate in the tumor microenvironment,and inhibits the function and activity of immune cells,promoting tumor progression.The article reviews the CCL2/CCR2 signaling axis and its role in tumors and tumor microenvironment,with particular focus on the advances in clinical research on drugs targeting CCL2/CCR2 signaling axis,in order to gain an in-depth and overall understanding of the mechanism of action of CCL2/CCR2 axis in tumor progression and develop more effective anti-tumor immunotherapeutic agents.

CCL2CCR2cancer immunotherapytumor microenvironmentimmunosuppressive cells

崔珍珍、赵一凡、孙玉、孟佳怡、康迪、胡立宏

展开 >

南京中医药大学药学院, 江苏省中药功效物质重点实验室, 南京 210023

CCL2 CCR2 肿瘤免疫治疗 肿瘤微环境 免疫抑制细胞

国家自然科学基金江苏省研究生实践创新计划项目

82104270KYCX22_2035

2024

中国药科大学学报
中国药科大学

中国药科大学学报

CSTPCD北大核心
影响因子:0.655
ISSN:1000-5048
年,卷(期):2024.55(1)
  • 63